Targeting Oncogenic Mutant p53 and BCL-2 for Small Cell Lung Cancer Treatment

por Neely, Victoria, Manchikalapudi, Alekhya, Nguyen, Khanh, Dalton, Krista, Hu, Bin, Koblinski, Jennifer E., Faber, Anthony C., Deb, Sumitra, Harada, Hisashi
Publicado 2023

High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition

por Cai, Jinyang, Jacob, Sheeba, Kurupi, Richard, Dalton, Krista M., Coon, Colin, Greninger, Patricia, Egan, Regina K., Stein, Giovanna T., Murchie, Ellen, McClanaghan, Joseph, Adachi, Yuta, Hirade, Kentaro, Dozmorov, Mikhail, Glod, John, Boikos, Sosipatros A., Ebi, Hiromichi, Hao, Huaixiang, Caponigro, Giordano, Benes, Cyril H., Faber, Anthony C.
Publicado 2022

Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1

por Kurupi, Richard, Floros, Konstantinos V., Jacob, Sheeba, Chawla, Ayesha T., Cai, Jinyang, Hu, Bin, Puchalapalli, Madhavi, Coon, Colin M., Khatri, Rishabh, Crowther, Giovanna Stein, Egan, Regina K., Murchie, Ellen, Greninger, Patricia, Dalton, Krista M., Ghotra, Maninderjit S., Boikos, Sosipatros A., Koblinski, Jennifer E., Harada, Hisashi, Sun, Yue, Morgan, Iain M., Basu, Devraj, Dozmorov, Mikhail G., Benes, Cyril H., Faber, Anthony C.
Publicado 2022